American biopharmaceuticals focused on antivirals
Nigeria faces a humanitarian gap as PEPFAR funding cuts drive patients toward unproven Islamic remedies. While lenacapavir rollout offers hope in the UK, access gaps persist in low-income regions where cost and infrastructure block lifesaving care.
Novo has laid out a plan to diversify beyond Wegovy and Ozempic as it faces looming exclusivity losses. Capital Markets Day signals a push into cardiovascular, liver and blood disorders with a target to expand its pipeline, while investors question credibility and near-term milestones amid a evolving GLP-1 landscape dominated by Lilly.
Uganda reports HIV prevalence stable at 5.9% with 1.496 million adults living with HIV; 85.3% know their status, 99.1% on treatment, 96.5% virally suppressed. In MENA, lenacapavir's global rollout shows affordability gaps and uneven access; six generic manufacturers will produce cheaper versions, but many countries remain excluded, raising concerns over reach of the prevention option.